AMERICAN BULLS: MONDEY, CONFIRMATION: SELL!!
Signal Update
Our system’s recommendation today is to SELL. The BEARISH ONE BLACK CROW pattern finally received a confirmation because the prices crossed the confirmation level which was at 14,5800, and our valid average selling price stands now at 14,5000. The previous BUY recommendation was issued on 22/05/2014, 22 days ago, when the stock price was 9,9600. Since then VNDA has risen by +45,58%.
Market Outlook
We may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Today’s candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a SELL signal is generated. You still have time to follow the signal and then you may start checking other securities for a bullish bet. Less
Signal Update
Our system’s recommendation today is to SELL. The BEARISH ONE BLACK CROW pattern finally received a confirmation because the prices crossed the confirmation level which was at 14,5800, and our valid average selling price stands now at 14,5000. The previous BUY recommendation was issued on 22/05/2014, 22 days ago, when the stock price was 9,9600. Since then VNDA has risen by +45,58%.
Market Outlook
We may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Today’s candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a SELL signal is generated. You still have time to follow the signal and then you may start checking other securities for a bullish bet. Less
Recent VNDA News
- Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis • PR Newswire (US) • 05/27/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:49:38 PM
- Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences • PR Newswire (US) • 05/07/2026 10:44:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:01:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:06:17 PM
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/06/2026 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:14 AM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/01/2026 08:35:00 PM
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • PR Newswire (US) • 04/29/2026 08:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/29/2026 08:08:37 PM
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence • PR Newswire (US) • 04/28/2026 11:12:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:35:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:50:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:48:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 09:23:06 PM
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors • PR Newswire (US) • 04/22/2026 09:13:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:38:37 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:37:04 PM
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines • PR Newswire (US) • 04/09/2026 03:02:00 PM
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists • PR Newswire (US) • 04/08/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:32 PM
- Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods • PR Newswire (US) • 03/19/2026 08:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:54:11 PM
